<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641836</url>
  </required_header>
  <id_info>
    <org_study_id>IPAH-EPC-2</org_study_id>
    <nct_id>NCT00641836</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension</brief_title>
  <official_title>One-Year Follow-Up of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <brief_summary>
    <textblock>
      Recent researches indicate that impairment of vascular and endothelial homeostasis plays a&#xD;
      major role in the initiation and development of IPAH.We have recently reported the safety and&#xD;
      feasibility data for autologous endothelial progenitor cells (EPCs) injection in patients&#xD;
      with IPAH. Yet many questions remain unanswered: what is the ideal quantity of EPCs for&#xD;
      therapy, the duration of the therapeutic effect, and moreover, the potential toxicity of such&#xD;
      therapy. To help answer these questions, we designed the one year follow-up to investigate&#xD;
      the safety and efficacy of autologous EPCs injection in patients with IPAH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">98</enrollment>
  <condition>Idiopathic Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplantation of autologous endothelial progenitor cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The inclusion criteria included a base-line six minute walking distance between 100&#xD;
             and 450 m&#xD;
&#xD;
          -  A resting mean pulmonary-artery pressure greater than 30 mm Hg&#xD;
&#xD;
          -  A pulmonarycapillary wedge pressure of less than 15 mm Hg&#xD;
&#xD;
          -  Pulmonary vascular resistance greater than 240 dyn•sec•cm-5&#xD;
&#xD;
          -  18-60 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The exclusion criteria included secondary pulmonary hypertension as a result of heart&#xD;
             disease&#xD;
&#xD;
          -  Pulmonary disease&#xD;
&#xD;
          -  Sleep-associated disorders&#xD;
&#xD;
          -  Chronic thromboembolic disease&#xD;
&#xD;
          -  Autoimmune or collagen vascular disease&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  New York Heart Association functional class IV&#xD;
&#xD;
          -  Major bleeding requiring blood transfusion&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Renal dysfunction&#xD;
&#xD;
          -  Evidence for malignant diseases were excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junzhu Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, the First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, Zhu JH, Chen JZ. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007 Apr 10;49(14):1566-71. Epub 2007 Mar 27.</citation>
    <PMID>17418297</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>March 18, 2008</last_update_submitted>
  <last_update_submitted_qc>March 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

